150 related articles for article (PubMed ID: 25744435)
1. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
2. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
5. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
6. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
7. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
8. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
[TBL] [Abstract][Full Text] [Related]
10. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
11. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
[TBL] [Abstract][Full Text] [Related]
12. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
14. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
16. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin.
Miyamoto R; Tani H; Ikeda T; Saima H; Tamura K; Bonkobara M
Res Vet Sci; 2021 Mar; 135():412-415. PubMed ID: 33160684
[TBL] [Abstract][Full Text] [Related]
17. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
18. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
20. Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Miyamoto R; Kurita S; Tani H; Ikeda T; Ishizaka M; Saima H; Kobayashi M; Tamura K; Bonkobara M
Vet J; 2018 Oct; 240():31-36. PubMed ID: 30268330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]